Literature DB >> 24477458

Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways.

Santosh Kumar1, Taraka R Donti, Navneet Agnihotri, Kapil Mehta.   

Abstract

Aberrant glucose metabolism characterized by high levels of glycolysis, even in the presence of oxygen, is an important hallmark of cancer. This metabolic reprogramming referred to as the Warburg effect is essential to the survival of tumor cells and provides them with substrates required for biomass generation. Molecular mechanisms responsible for this shift in glucose metabolism remain elusive. As described herein, we found that aberrant expression of the proinflammatory protein transglutaminase 2 (TG2) is an important regulator of the Warburg effect in mammary epithelial cells. Mechanistically, TG2 regulated metabolic reprogramming by constitutively activating nuclear factor (NF)-κB, which binds to the hypoxia-inducible factor (HIF)-1α promoter and induces its expression even under normoxic conditions. TG2/NF-κB-induced increase in HIF-1α expression was associated with increased glucose uptake, increased lactate production and decreased oxygen consumption by mitochondria. Experimental suppression of TG2 attenuated HIF-1α expression and reversed downstream events in mammary epithelial cells. Moreover, downregulation of p65/RelA or HIF-1α expression in these cells restored normal glucose uptake, lactate production, mitochondrial respiration and glycolytic protein expression. Our results suggest that aberrant expression of TG2 is a master regulator of metabolic reprogramming and facilitates metabolic alterations in epithelial cells even under normoxic conditions. A TG2-induced shift in glucose metabolism helps breast cancer cells to survive under stressful conditions and promotes their metastatic competence.
© 2013 UICC.

Entities:  

Keywords:  EMT; HIF-1α; NF-κB; drug resistance; metabolism; metastasis

Mesh:

Substances:

Year:  2014        PMID: 24477458     DOI: 10.1002/ijc.28623

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

1.  Transglutaminase 2 in pulmonary and cardiac tissue remodeling in experimental pulmonary hypertension.

Authors:  Krishna C Penumatsa; Deniz Toksoz; Rod R Warburton; Mousa Kharnaf; Ioana R Preston; Navin K Kapur; Chaitan Khosla; Nicholas S Hill; Barry L Fanburg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-03       Impact factor: 5.464

2.  Role of hypoxia-induced transglutaminase 2 in pulmonary artery smooth muscle cell proliferation.

Authors:  Krishna C Penumatsa; Deniz Toksoz; Rod R Warburton; Andrew J Hilmer; Tiegang Liu; Chaitan Khosla; Suzy A A Comhair; Barry L Fanburg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-08-15       Impact factor: 5.464

Review 3.  Transglutaminase 2: Friend or foe? The discordant role in neurons and astrocytes.

Authors:  Breandan R Quinn; Laura Yunes-Medina; Gail V W Johnson
Journal:  J Neurosci Res       Date:  2018-03-23       Impact factor: 4.164

4.  Tissue transglutaminase expression is necessary for adhesion, metastatic potential and cancer stemness of renal cell carcinoma.

Authors:  Yesim Bagatur; Ayca Zeynep Ilter Akulke; Ajna Bihorac; Merve Erdem; Dilek Telci
Journal:  Cell Adh Migr       Date:  2017-07-14       Impact factor: 3.405

5.  Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication.

Authors:  Victoria O Shender; Marat S Pavlyukov; Rustam H Ziganshin; Georgij P Arapidi; Sergey I Kovalchuk; Nikolay A Anikanov; Ilya A Altukhov; Dmitry G Alexeev; Ivan O Butenko; Alexey L Shavarda; Elena B Khomyakova; Evgeniy Evtushenko; Lev A Ashrafyan; Irina B Antonova; Igor N Kuznetcov; Alexey Yu Gorbachev; Mikhail I Shakhparonov; Vadim M Govorun
Journal:  Mol Cell Proteomics       Date:  2014-09-30       Impact factor: 5.911

6.  Glycolysis regulated transglutaminase 2 activation in cardiopulmonary fibrogenic remodeling.

Authors:  Chinmayee D Bhedi; Sabina Nasirova; Deniz Toksoz; Rod R Warburton; Kevin J Morine; Navin K Kapur; Jonas B Galper; Ioana R Preston; Nicholas S Hill; Barry L Fanburg; Krishna C Penumatsa
Journal:  FASEB J       Date:  2019-11-28       Impact factor: 5.191

7.  Tissue transglutaminase 2 exerts a tumor-promoting role in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Chengbo Yu; Qing Cao; Ping Chen; Shigui Yang; Xianli Gong; Min Deng; Bing Ruan; Lanjuan Li
Journal:  Tumour Biol       Date:  2016-10-25

8.  Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences.

Authors:  Delisha A Stewart; Jason H Winnike; Susan L McRitchie; Robert F Clark; Wimal W Pathmasiri; Susan J Sumner
Journal:  J Proteome Res       Date:  2016-08-03       Impact factor: 4.466

Review 9.  Transglutaminase is a tumor cell and cancer stem cell survival factor.

Authors:  Richard L Eckert; Matthew L Fisher; Dan Grun; Gautam Adhikary; Wen Xu; Candace Kerr
Journal:  Mol Carcinog       Date:  2015-08-10       Impact factor: 4.784

10.  Infection-driven activation of transglutaminase 2 boosts glucose uptake and hexosamine biosynthesis in epithelial cells.

Authors:  Benoit Maffei; Marc Laverrière; Yongzheng Wu; Sébastien Triboulet; Stéphanie Perrinet; Magalie Duchateau; Mariette Matondo; Robert L Hollis; Charlie Gourley; Jan Rupp; Jeffrey W Keillor; Agathe Subtil
Journal:  EMBO J       Date:  2020-03-05       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.